Terns Pharmaceuticals To Highlight New Preclinical Data For TERN-601 Program In Obesity At The American Diabetes Association's 83rd Annual Scientific Sessions
Portfolio Pulse from Happy Mohamed
Terns Pharmaceuticals (NASDAQ:TERN) will present new preclinical data on TERN-601, a novel oral GLP-1R agonist for obesity treatment, at the American Diabetes Association's 83rd Annual Scientific Sessions. The data shows TERN-601 suppresses food intake and improves glucose tolerance in transgenic mice.
May 22, 2023 | 8:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Terns Pharmaceuticals will present promising preclinical data on TERN-601, a potential oral treatment for obesity, at the American Diabetes Association's 83rd Annual Scientific Sessions.
The presentation of positive preclinical data on TERN-601 at a prestigious conference could generate interest in Terns Pharmaceuticals and its product pipeline. This may lead to increased investor confidence and a potential short-term positive impact on TERN's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100